Enlivex, a Nasdaq-listed biopharma company, has announced plans to acquire $212 million worth of Rain, the native token of the Rain Protocol. The acquisition will be funded by selling 212 million shares at $1 each. Enlivex aims to enhance shareholder value by becoming the largest corporate holder of Rain and utilizing it for yield generation. Rain Protocol, valued at $1.8 billion, is a prediction market protocol launched on the Arbitrum blockchain in 2023.